Free Trial

Hookipa Pharma Q4 2023 Earnings Report

Hookipa Pharma logo
$0.82 -0.03 (-3.00%)
As of 04:00 PM Eastern

Hookipa Pharma EPS Results

Actual EPS
-$1.10
Consensus EPS
-$2.00
Beat/Miss
Beat by +$0.90
One Year Ago EPS
N/A

Hookipa Pharma Revenue Results

Actual Revenue
$7.41 million
Expected Revenue
$3.60 million
Beat/Miss
Beat by +$3.81 million
YoY Revenue Growth
N/A

Hookipa Pharma Announcement Details

Quarter
Q4 2023
Time
N/A
Remove Ads

Hookipa Pharma Earnings Headlines

Hookipa Pharma (HOOK) Expected to Announce Earnings on Friday
Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Hookipa Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hookipa Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hookipa Pharma and other key companies, straight to your email.

About Hookipa Pharma

Hookipa Pharma (NASDAQ:HOOK)., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View Hookipa Pharma Profile

More Earnings Resources from MarketBeat